

Congenital Muscle Diseases: Congenital Muscular

Dystrophies and Structural Congenital Myopathies

Edmar Zanoteli



Associate Professor Department of Neurology Medical School of the University of São Paulo, Brazil

(edmar.zanoteli@usp.br)





Faculty Disclosure

X No, nothing to disclose

Yes, please specify:

Company Name	Honoraria/ Expenses	Consulting/ Advisory Board	Funded Research	Royalties/ Patent	Stock Options	Ownership/ Equity Position	Employee	Other (please specify)

Learning objectives

- 1. Recognize the clinical aspects of the most common forms of congenital muscle diseases
- 2. Recognize the most common subtypes of the congenital muscle diseases
- 3. Know the most important lab exams to diagnose
- 4. Know the key points for the treatment of these patients



Congenital muscle diseases are heterogeneous group of myopathies characterized by hypotonia, weakness and skeletal deformities noted in the first year of life, with a dystrophic aspect on muscle biopsy (congenital muscular dystrophies) or with structural changes on muscle biopsy (structural congenital myopathies).

The most common forms of congenital muscular dystrophies are caused by deficiency of merosin, collagen 6 and selenoprotein and hypoglycosylation of alpha-dystroglycan. And the most common forms of structural congenital myopathies are nemaline, central-core/minicore, centronuclear and congenital disproportion of fibers myopathies.

 Brain involvement occurs in only few subtypes, such as in the deficiency of merosin and alpha-dystroglycans

 Most of them develop a stable or slowly progressive course, but with important skeletal deformities and pulmonary involvement

 No specific therapy is available, and a multidisciplinary approach is needed, including physical therapy, cardiopulmonary evaluation, orthopedist and nutrition specialists

Common causes of hypotonia in children!

✓ **Central nervous system involvement** (hypoxicischemic injury, infections, cerebral dysgenesis)

✓ Diseases of the motor unit (spinal muscular atrophy, peripheral neuropathies, miastenia, myopathies)

✓ Non-neurological conditions (hypothyroidism, systemic illness, Down's syndrome, Prader-Willi, Trisomy 21)

Common causes of motor unit involvement!



Defining congenital muscular dystrophies!

Heterogeneous group of myopathies characterized by hypotonia and weakness noted in the first year of life, and with a <u>dystrophic aspect on muscle biopsy</u> without specific structural alterations of the muscle fibers



The incidence of all forms of congenital muscular dystrophies has been estimated at 1/21,500 with a prevalence of 1/125,000 (*Mostacciuolo ML, 1996*)

Defining congenital muscular dystrophies! Classification

- Abnormalities of extracellular matrix proteins (LAMA2merosin, COL6A1, COL6A2, COL6A3)
- Abnormalities of α-dystroglycan glycosylation (fukutin, POMGnT1, POMT1, POMT2, FKRP, LARGE)

- Abnormalities of nuclear proteins (Lamin A/C)
- Abnormalities at the level of the endoplasmic reticulum (selenoprotein N1)

Congenital Muscular Dystrophies

Deficiency of Merosin



- 40-50% of the CMD
- Increase of CK (>5X)
- CNS white matter changes
- Normal cognition



Merosin

Dystrophin

Hypoglycosylation of α -dystroglycan

 Post-translational modification of O-mannosylglycans on α-dystroglycan is required for its binding to laminin, agrin and perlecan on the extracellular matrix (ECM)

- Hypoglycosylation of α-dystroglycan due to glycosyltransferases deficiency reduce its binding to ECM components weakening the sarcolemma
- At least 15 glycosyltransferases were identified causing hypoglycosylation of α -dystroglycan



- **POMT1 and POMT2**: Initial link between mannose and alpha-DG (mannosylation)
- **POMGnT1**: Add residues of GlcNAc (transference of N-acetylglucosamine) to alpha-DG
- Fukutin and fukutin related protein (FKRP): Synthesis of tetrasaccharides ?

Spectrum of the involvement of α -dystroglycanophaties

Central nervous system

Supratentorial

- Agyria
- Encephalocele
- Pachygyria
- Lissencephaly
- Abnormalities of white matter
- Hydrocephalus

Infratentorial

- Cerebellar hypoplasia
- Cerebellar cysts
- Pons and brainstem dysplasia

Eye

- Myopia
- Microphthalmia
- Retina defects
- Defects of anterior chamber

Skeletal muscle

- Mild to severe weakness and hypotonia
- Increase of CK
- Reduction of merosin stain on muscle biopsy
- Hypoglycosylated ADG in the muscle biopsy

Collagen 6 deficiency



keloid

Follicular hyperkeratosis

Congenital Muscular Dystrophies Rigid spine – Selenoprotein deficiency

- Severe respiratory insufficiency
- Mild to moderate limb and walking involvement



Intense axial weakness

Limitation of spinal movements

Scoliosis

Normal CK level

SEPN1 (1p) gene

- Glycoprotein localized at ER and cell membrane
- Protection against oxidative stress



Mini-cores

Congenital Muscular Dystrophies Other forms

- Lamin A/C (nuclear protein)
- Nesprin 1 (nuclear protein)
- CHKB (mitochondrial CMD)
- ITGA7 (integrin α7)
- ITGA9 (integrin α9)





(Mercure & Muntoni, 2012)

Key points for the diagnosis of CMD subtypes

Merosin	 Not acquisition of walking Increased CK White matter changes on brain MRI, but normal cognition
α-DG	 Mild to severe weakness and hypotonia CNS abnormalities Cognitive alterations and epilepsy Increased CK
Collagen 6	 Distal joint hyperlaxity Keloids and follicular hyperkeratosis Normal CK
SEPN1	 Rigid spine Early respiratory insufficiency Normal CK

Structural congenital myopathies! What are they?

• Heterogeneous group of myopathies that typically present in childhood with weakness and hypotonia

Symptoms usually present at birth but can present at any age Normal or mild increase of serum CK level

• Historically defined and classified by characteristic features on muscle biopsy: 4 predominant subtypes

Core myopathies (central core disease and multi/minicore myopathy) Centronuclear myopathies Nemaline myopathies Congenital Fiber Type Disproportion

 Current standards for diagnosis include clinical, histopathological, imaging and genetic considerations

Structural Congenital Myopathies clinical aspects

Atrofia muscular global **Deformidades** caixa torácica Fraqueza apendicular difusa Fraqueza paravertebral Craniofacial involvement Stable or slowly progressive course

Nemaline Myopathy

"Rods" are formed at Z line of sarcomere





Nebulin, α -actin, tropomyosins and troponins interact with one another during muscle contraction

Central-Core Myopathy *RYR1 gene* (ryanodine receptor)



Areas devoid of oxidative
 activity located on the central
 part of the fibers, detected by
 NADH and SDH stains

- Structured: normal myofibrils
- Non-structured: disorganized myofibrils
- Usually the muscle tissue is non dystrophic

Mini/multi-cores Myopathy





Multiple areas devoid of oxidative activity into de fibers (mini-cores)

• RYR1

- Selenoprotein N,1
- Titin
- Megf10 (expression in satellite cells)
- Childhood onset
- Clinical variability
- General weakness and hypotonia
- Craniofacial involvement
- Stable course

Centronuclear myopathy

Delay of maturation of muscle fibers?



- Spiro (1966)
- Myotubos: fetal period
- Abnormal persistence of myotubular aspect

Increase of the oxidative activities on the central parts and on the subsarcolemmal region of the fibers

Centronuclear myopathy

Myotubular

Neonatal severe form

- Xq28 *MTM1* gene
- Severe neonatal involvement

Childhood onset form

- Anphiphysin-1 (BIN1) 2q
- RYR1 gene
- Autosomal recessive



Adult onset form

- Dynamin 2 gene
- Autosomal dominant
- Mild clinical form

Congenital Disproportion of Fibers



Type 1 fibers lesser than 12% of type 2 fibers

Genes involved

α-actin *(ACTA1*)

Tropomyosin 3 (TPM3)

Tropomyosin 2 (TPM2)

Ryanodine receptor gene (RYR1)



Clarke, 2011

Different degrees of fiber type disproportion can be seem in other types of neuromuscular and CNS diseases

Diagnosis of exclusion !



Congenital Muscle Diseases

Congenital myotonic dystrophy (Steinert)



- Woman with Steinert's diseases: risk of 80%
- Severe neonatal involvement: sucking and respiratory problems, facial involvement, skeletal deformities
- Stable course on childhood: facial involvement, cognitive impairment



Congenital Muscle Diseases Treatment

- No specific treatment is available
- Symptomatic treatment
- Genetic counseling
- Rehabilitation



Scoliosis



Contractures

- Skeletal deformities
- Nutrition
- Pulmonary insufficiency

Congenital Muscle Diseases References

- 1. Ravenscroft G, et al. Pathophysiological concepts in the congenital myopathies: blurring the boundaries, sharpening the focus. Brain. 2015, 138(Pt 2):246-68.
- 2. Endo T. Glycobiology of α -dystroglycan and muscular dystrophy. J Biochem. 2015, 157(1):1-12.
- 3. Gilbreath HR, et al. Congenital myopathies and muscular dystrophies. Neurol Clin. 2014, 32(3):689-703.
- 4. Bönnemann CG, et al. Diagnostic approach to the congenital muscular dystrophies. Neuromuscul Disord. 2014, 24(4):289-311.
- 5. North KN, et al. Approach to the diagnosis of congenital myopathies. Neuromuscul Disord. 2014, 24(2):97-116.
- 6. Snoeck M, et al. RYR1-related myopathies: a wide spectrum of phenotypes throughout life. Eur J Neurol. 2015, 22(7):1094-112.
- McMillan HJ. Congenital muscular dystrophies: New evidence-based guidelines for the diagnosis and management of this evolving group of muscle disorders. Muscle Nerve. 2015, 51(6):791-2.
- 8. Kang PB, et al. Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & amp; Electrodiagnostic Medicine. Neurology. 2015, 31;84(13):1369-78.